US Supreme Court verdict shines on Caraco in generic 'Orange Book' battle
This article was originally published in SRA
Executive Summary
Sun Pharmaceutical's US unit Caraco Pharmaceutical won a major victory for all generic drug makers on 17 April when the US Supreme Court ruled in a unanimous decision that those firms may employ the so-called counterclaim provision of the Hatch-Waxman Act to force brand-name drug manufacturers to correct inaccurate descriptions of their medication's patent as covering a particular method of using the product1.